ClinicalTrials.gg
CompletedNCT03008161Updated Aug 15, 2019

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

A Phase 1 interventional study of NPT088 and Placebo in Alzheimer Disease, sponsored by Proclara Biosciences, Inc.. Completed at 23 sites in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-08-15.

Sponsored by Proclara Biosciences, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
745th of 1,609
83 · median 73
Started
2016
with 86 others
Phase 1
304 of 1,940
31 open now
Registered
830th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 745th largest by enrollment of the 1,609 interventional ones that give a count, is one of 87 that started in 2016, is one of 304 in phase 1, and was the 830th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and tolerability of multiple doses of NPT088 in patients with mild to moderate probable Alzheimer's Disease. The study will also evaluate the pharmacokinetics, immunogenicity and exploratory pharmacodynamic characteristics of multiple doses of NPT088.

Read the detailed description

This study is a multicenter Phase 1, randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation safety and tolerability study of NPT088 or placebo in patients with Probable AD with a MMSE score of 16-27. Enrolled patients will receive an intravenous infusion of NPT088 or placebo once a month for six months during this study. Four dose cohorts are planned with the first two cohorts enrolling 9 patients each (6 NPT088: 3 placebo) and the final two cohorts enrolling 24 patients each (16 NPT088: 8 placebo) for a total of 66 patients (44 NPT088: 22 placebo).

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • GAIM
  • amyloid
  • anti-aBeta
  • anti-tau
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: For enrollment in the study, participants must

  • be between 50 and 85 years of age, inclusive
  • have a (MMSE) scores between 16-27 (inclusive)
  • have a Modified Hachinski Score of less than or equal to 4
  • have a diagnosis of Probable Alzheimer's Disease (AD) according to consensus criteria defined by the National Institute on Aging-Alzheimer's Association work group
  • have a Clinical Dementia Rating Scale (CDR) of 0.5 or 1.0, with the memory box score equal to or greater than 0.5
  • have a positive florbetapir positron emission tomography (PET) amyloid scan
  • consent to apolipoprotein E (ApoE) genotyping
  • be willing to undergo repeat Magnetic Resonance Imaging (MRI) and PET imaging
  • be on stable doses of allowed medications for at least 30 days prior to Screening. Concurrent treatment with cholinesterase inhibitors and/or memantine is allowed
  • be in good healthy apart from the clinical diagnosis of AD
  • have a dedicated Caregiver who provides care at least 4 hours a day for 4 days a week and will provide for their participation

Exclusion Criteria: For enrollment in the study, participants must NOT:

  • have a history of, or screening MRI indicative of any significant brain abnormality
  • have any major medical illness or unstable medical condition or in the opinion of the Investigator have any reason that may interfere with the participants ability to comply with the study procedures and abide by study restrictions or with the ability to interpret safety data
  • reside in a nursing home or need 24-hour care and supervision
  • take excluded medications
  • have exclusionary values on the Screening blood and urine sample
  • have been treated with immunomodulators to treat AD
  • have participated in an drug or device study within 90 days
  • have a known allergy to study drug
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive monthly IV infusions of either low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months

    Drug: NPT088 · Drug: Placebo

  • Experimental
    Cohort 2

    Participants will receive monthly IV infusions of either mid-low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months

    Drug: NPT088 · Drug: Placebo

  • Experimental
    Cohort 3

    Participants will receive monthly IV infusions of either mid-high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months

    Drug: NPT088 · Drug: Placebo

  • Experimental
    Cohort 4

    Participants will receive monthly IV infusions of either high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months

    Drug: NPT088 · Drug: Placebo

Interventions

  • DrugNPT088

    IgG1 Fc-GAIM fusion protein, a recombinant fusion protein

    Also known as: IgG1, fusion protein, GAIM, anti-Abeta, anti-Tau

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Number of patients with adverse events

    Time frame: Baseline to Week 32

Secondary outcomes

  1. Multiple dose pharmacokinetic (PK) serum concentrations of NPT088

    Time frame: Up to Week 32

  2. Multiple dose PK CSF concentrations of NPT088

    Time frame: Up to Week 32

  3. Multiple dose immunogenicity of NPT088

    Time frame: Up to Week 32

Other outcomes

  1. Change from baseline in florbetapir-fluorine-18 positron emission tomography (PET) imaging in certain brain areas

    Time frame: Baseline and Week 24

  2. Change from baseline in [18F] MNI-960 PET imaging in certain brain areas

    Time frame: Baseline and Week 24

  3. Change in CSF or blood biomarkers

    Time frame: Up to Week 32

07

Study locations

23 sites
  • ATP Clinical Research, Inc.
    Costa Mesa, California 92626, United States
  • Neurology Center of North Orange County
    Fullerton, California 92835, United States
  • Collaborative Neuroscience Network
    Long Beach, California 90806, United States
  • Southern California Research
    Simi Valley, California 93065, United States
  • Associated Neurologists of Southern Connecticut
    Fairfield, Connecticut 06824, United States
  • JEM Research Institute
    Atlantis, Florida 33462, United States
  • Indago Research and Health Center
    Hialeah, Florida 33012, United States
  • Alzheimer's Research and Treatment Center
    Lake Worth, Florida 33449, United States
  • Miami Jewish Health Systems
    Miami, Florida 33137, United States
  • Medical Research Group of Central Florida
    Orange City, Florida 32763, United States
  • Compass Research
    Orlando, Florida 32806, United States
  • Progressive Medical Research
    Port Orange, Florida 32137, United States
  • Axiom Clinical Research
    Tampa, Florida 33609, United States
  • Compass-The Villages
    The Villages, Florida 32162, United States
  • Medical Research and Health Education Foundation
    Columbus, Georgia 31909, United States
  • NeuroStudies LLC
    Decatur, Georgia 30033, United States
  • Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • Neurological Associates of Albany
    Albany, New York 12208, United States
  • Integrative Clinical Trials, Inc.
    Brooklyn, New York 11229, United States
  • Alzheimer's Memory Center
    Charlotte, North Carolina 28270, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Abington Neurological Associates, Ltd
    Willow Grove, Pennsylvania 19090, United States
  • Neurology Clinic, PC
    Cordova, Tennessee 38018, United States
08

References and documents

Publications

  • Krishnan R, Tsubery H, Proschitsky MY, Asp E, Lulu M, Gilead S, Gartner M, Waltho JP, Davis PJ, Hounslow AM, Kirschner DA, Inouye H, Myszka DG, Wright J, Solomon B, Fisher RA. A bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies. J Mol Biol. 2014 Jun 26;426(13):2500-19. doi: 10.1016/j.jmb.2014.04.015. Epub 2014 Apr 22. PubMed 24768993 ↗
  • Levenson JM, Schroeter S, Carroll JC, Cullen V, Asp E, Proschitsky M, Chung CH, Gilead S, Nadeem M, Dodiya HB, Shoaga S, Mufson EJ, Tsubery H, Krishnan R, Wright J, Solomon B, Fisher R, Gannon KS. NPT088 reduces both amyloid-beta and tau pathologies in transgenic mice. Alzheimers Dement (N Y). 2016 Jul 14;2(3):141-155. doi: 10.1016/j.trci.2016.06.004. eCollection 2016 Sep. PubMed 29067301 ↗
  • Krishnan R, Hefti F, Tsubery H, Lulu M, Proschitsky M, Fisher R. Conformation as the Therapeutic Target for Neurodegenerative Diseases. Curr Alzheimer Res. 2017;14(4):393-402. doi: 10.2174/1567205014666170116152622. PubMed 28093972 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Feb 2019, 26 months.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 26 months is above that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2016
First posted
Jan 2, 2017
StartActual
Dec 2016
Primary completionActual
Feb 6, 2019
CompletionActual
Feb 6, 2019
Last update
Aug 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03008161
Lead sponsor
Proclara Biosciences, Inc.
Collaborators
Alzheimer's Association
Responsible party
Sponsor
First posted
Jan 2, 2017
Start date
Dec 2016
Primary completion
Feb 6, 2019
Completion
Feb 6, 2019
Last update
Aug 15, 2019

Study contacts

Proclara Biosciences
study director · Proclara

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulin G

Start the discussion